Portola Pharmaceuticals

Portola Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops therapeutics for acute and chronic cardiovascular and autoimmune/inflammatory diseases. The company's products include PRT054021, an oral factor Xa inhibitor for the prevention and treatment of deep vein thrombosis and pulmonary embolism after orthopedic surgery; for stroke prevention in patients with atrial fibrillation; and for secondary prevention of myocardial infarction and stroke. Its products also include PRT060128, an oral and intravenous ADP receptor antagonist for the treatment of patients with acute coronary syndrome; for the prevention of cardiovascular events in patients undergoing percutaneous coronary intervention; and for secondary prevention of myocardial infarction and stroke. In addition, the company's products include PRT062607, an oral Syk-specific kinase inhibitor for treating chronic inflammatory diseases and Rheumatoid Arthritis (RA) which is used to treat certain cancers including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Portola Pharmaceuticals, Inc. was founded in 2003 and is based in South San Francisco, California.

Portola Pharmaceuticals (PTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Portola Pharmaceuticals (PTLA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Portola Pharmaceuticals' products present clinicians with many headaches, and the company's equity has been beaten down recently.

Portola Pharmaceuticals: Headaches For Us, Buying Opportunity For Investors

The company's still struggling to transition from clinical stage to commercial stage, but it's making progress.

3 Key Takeaways From Portola Pharmaceuticals' Quarterly Results

Portola Pharmaceuticals' (PTLA) CEO Scott Garland on Q1 2019 Results - Earnings Call Transcript

First-quarter financial results are failing to spark investor optimism on concerns over cash burn.

Why Portola Pharmaceuticals Is Tumbling 14.5% Today

Portola Pharmaceuticals (PTLA) delivered earnings and revenue surprises of 0.00% and 6.38%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Portola Pharmaceuticals (PTLA) Reports Q1 Loss, Tops Revenue Estimates

This commercial-stage company's success depends heavily on the demand for one drug.

Portola Pharmaceuticals: Is It Still a Buy?

Portola Pharmaceuticals is a growth company that is undergoing strong fundamentals development.

News for Portola Pharmaceuticals Stock (PTLA)